綠葉製藥(02186.HK)LY 03003治療帕金森病臨床試驗達預設終點
綠葉製藥(02186.HK)公布,集團在研新藥-注射用羅替戈汀緩釋微球(LY 03003)治療帕金森病的中國Ⅲ期臨床試驗達到預設終點。結果表明,LY 03003 治療早期原發性帕金森病安全有效,可全面改善帕金森病運動症狀。
LY 03003為集團長效緩釋制劑平台開發的重點中樞神經系統在研產品之一。目前,在中國、中國、美國、歐洲和日本市場進行同步開發。集團計劃在在中國、美國、日本、歐洲及其他國家註冊和上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.